EGFR and gastric carcinoma: In gastric carcinoma, for instance, Hao et al. (2024) demonstrated that low GSN expression is associated with shorter overall survival and poorer clinical outcomes, suggesting that GSN acts as a putative tumor suppressor in this context by potentially modulating key signaling pathways such as the c-erbB/EGFR and PI3K/Akt cascades [34].